Document:

EX-10.12

 Exhibit 10.12 

Global Blood Therapeutics, Inc. 

Amended and Restated Severance and Change in Control Policy 

Adopted on July 23, 2015 

(amended and restated on January 6, 2016, July 5, 2017, July 26, 2017, 

December 13, 2017, March 13, 2018, July 23, 2019, October 16, 2019, January 7, 2020, 

May 26, 2020 and November 30, 2020) 

Benefits in Connection with a Sale Event. 

In connection with a Sale Event (as defined in the Global Blood Therapeutics, Inc. 2015 Stock Option and Incentive Plan (as may be amended or
restated, the “2015 Plan”)), employees of Global Blood Therapeutics, Inc. and its subsidiaries and affiliates (collectively, the “Company”) will be entitled to receive the following benefits in the event of a
termination of their employment or other service relationship with the Company (or its successor or acquirer) without Cause (as defined below) or for Good Reason (as defined below) within one (1) year after the closing of the Sale Event (the
“Change in Control Period”), subject to each such employee’s execution and non-revocation of a severance agreement within sixty (60) days following the date of such termination,
including a general release of claims acceptable to the Company or its successor or acquirer: 
  

	 	•	 	 Full acceleration of vesting of all outstanding equity-based awards, including stock options and restricted stock
units, under the 2015 Plan, the Company’s 2017 Inducement Equity Plan, and such additional equity incentive plans, arrangements and agreements (as each may be further amended or restated) covering employees of the Company as the Company’s
Board of Directors may adopt and approve from time to time (collectively, “Awards”), and for the sake of clarity, for any Awards accelerated in such manner that contain conditions and restrictions relating to the attainment of
performance goals, such performance goals will be deemed achieved at one hundred percent (100%) of target levels; and 

  

	 	•	 	 Payment of (a) severance in a lump sum in the amounts set forth below, (b) lump sum target
incentive bonus payouts in the amounts set forth below, equal to (i) a percentage, as set forth below, of the employee’s Target Incentive Bonus for the year in which the closing of the Sale Event occurred plus (ii) a prorated
incentive bonus payout for the portion of the year in which the closing of the Sale Event occurred, prorated based on employee’s Target Incentive Bonus and the date of termination of their employment or other service relationship with the
Company and (c) if the employee was participating in the Company’s group health plan immediately prior to the date of termination of his or her employment and elects COBRA health continuation, payment of a monthly cash payment for the
period set forth below or the employee’s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the employee if the
employee had remained employed by the Company, including, if applicable, the monthly employer contribution to a health savings account: 1 

 

	1 	 Benefits in the below table are reduced by Statutory Benefits as set forth in the “General
Provisions” section below. 

  
 1 

							
	 Position
	  	 Severance (Amount

of Base Salary)
	  	 Incentive Bonus
	  	 Benefits

Continuation

	Chief Executive Officer	  	18 months	  	150% Target Incentive Bonus and prorated Target Incentive Bonus	  	18 months
	Senior Management Team (“SMT”) members	  	12 months	  	100% Target Incentive Bonus and prorated Target Incentive Bonus	  	12 months
	Senior Vice Presidents and Vice Presidents (other than SMT members)	  	9 months	  	100% Target Incentive Bonus and prorated Target Incentive Bonus	  	9 months
	All Other Employees	  	6 months	  	100% Target Incentive Bonus and prorated Target Incentive Bonus	  	6 months

 Benefits Not in Connection with a Sale Event. 

Certain designated employees of the Company who execute a participation letter in substantially the form attached hereto as Exhibit A
will be entitled to receive the following benefits in the event of a termination of their employment or other service relationship with the Company (or its successor or acquirer) without Cause or for Good Reason outside of the Change in Control
Period, subject to each such employee’s execution and non-revocation of a severance agreement within sixty (60) days following the date of such termination, including a general release of claims
acceptable to the Company or its successor or acquirer: 
  

	 	•	 	 Payment of (a) severance in a lump sum in the amounts set forth below, (b) lump sum target incentive
bonus payouts in the amounts set forth below, equal to (i) a percentage, as set forth below, of the employee’s Target Incentive Bonus for the year in which such termination of employment or other service relationship occurred plus
(ii) a prorated incentive bonus payout for the portion of the year in which such termination of employment or other service relationship occurred, prorated based on employee’s Target Incentive Bonus and the date of termination of their
employment or other service relationship with the Company and (c) if the employee was participating in the Company’s group health plan immediately prior to the date of termination of his or her employment and elects COBRA health
continuation, payment of a monthly cash payment for the period set forth below or the employee’s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made
to provide health insurance to the employee if the employee had remained employed by the Company, including, if applicable, the monthly employer contribution to a health savings account: 2

  

	2 	 Benefits in the below table are reduced by Statutory Benefits as set forth in the “General
Provisions” section below. 

  
 2 

							
	 Position
	  	 Severance (Amount

of Base Salary)
	  	 Incentive Bonus
	  	 Benefits

Continuation

	Chief Executive Officer	  	12 months	  	100% Target Incentive Bonus and prorated Target Incentive Bonus	  	12 months
	SMT members	  	12 months	  	N/A	  	12 months

 General Provisions. 
 For
purposes of this Amended and Restated Severance and Change in Control Policy (this “Policy”), SMT members shall include (i) each individual who is then employed by the Company as an executive officer and (ii) such other
employees of the Company as may be designated by the Compensation Committee of the Board as SMT members for purposes of this Policy from time to time, which individuals specified in clauses (i) and (ii) shall each continue to be considered SMT
members for purposes of general severance and change in control severance benefits so long as they are employed with the Company as SMT members; provided that (a) if any such individual is employed by the Company in any other capacity (other
than serving as a SMT member), such individual will be eligible for benefits under this Policy in accordance with their then-applicable level of service as provided above; (b) any individual employed as the Company’s Chief Executive
Officer shall be eligible for the general severance and change in control severance benefits applicable to the Chief Executive Officer only so long as such individual is employed with the Company as the Chief Executive Officer (and if at any time
such individual remains employed by the Company but is not serving as the Chief Executive Officer, e.g., serving as a non-CEO SMT member, such individual will be eligible for benefits under this Policy in
accordance with his or her then-applicable level of service as provided above) and (c) any SMT member shall cease to be considered an SMT member for purposes of this Policy upon the termination of such individual’s employment with the
Company (except to the extent such termination triggers such individual’s entitlement to general severance or change in control severance benefits in accordance with this Policy). 

The amounts payable pursuant to this Policy shall be paid or commence to be paid within 60 days following the date of termination of employment, provided that
if the 60-day period begins in one calendar year and ends in a second calendar year, such payments shall be paid or commence to be paid in the second calendar year by the last day of such 60-day period. 
 Upon the consummation of a Sale Event, to the extent Section 280G of the Internal Revenue Code is
applicable to an employee, such employee shall be entitled to receive either: (a) payment of the full amounts set forth above to which the employee is entitled or (b) payment of such lesser amount that does not trigger excise taxes under
Section 280G, whichever results in the employee receiving a higher amount after taking into account all federal, state, and local income, excise and employment taxes. 

For purposes of this Policy, “Base Salary” shall mean the greater of (i) the base salary, at the annualized rate, in effect immediately prior
to the date of termination or (ii) the base salary, at the annualized rate, in effect immediately prior to the Sale Event, as applicable. 

  
 3 

 For purposes of this Policy, “Cause” shall mean (i) the employee’s dishonest statements
or acts with respect to the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business, including without limitation, the employee engaging in misappropriation of funds or
financial accounting improprieties; (ii) the employee’s commission of (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) the employee’s continued non-performance of his or her duties to the Company which has continued for thirty (30) or more days following written notice of such non-performance by the Company;
(iv) the employee’s material violation of the Company’s Code of Business Conduct and Ethics or of any of the Company’s other written employment, compliance or other policies as in effect from time to time; (v) the
employee’s material violation of any provision of any agreement(s) between the employee and the Company relating to noncompetition, nonsolicitation, confidentiality, nondisclosure and/or assignment of inventions; or (vi) the
employee’s failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve
documents or other materials known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation. 

For purposes of this Policy, “Good Reason” shall mean that the employee followed the “Good Reason Process” following the occurrence of
(a) a material diminution in the employee’s job responsibilities (provided that a change in the employee’s job title or reporting relationship shall not be deemed a material diminution in the employee’s job responsibilities),
(b) a material diminution in the employee’s base salary or (c) the relocation of the employee’s principal place of business to a location that is more than twenty-five (25) miles from the employee’s then-current
location of employment. “Good Reason Process” shall mean that (i) the employee reasonably determines in good faith that a “Good Reason” condition has occurred; (ii) the employee notifies the Company (or its successor)
in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii) the employee cooperates in good faith with the Company’s (or its successor’s) efforts, for a period not
less than 30 days following such notice (the “Cure Period”), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) the employee terminates his employment within 60 days
after the end of the Cure Period. If the Company or its successor cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred. 

For purposes of this Policy, “Target Incentive Bonus” shall mean the greater of (i) the target bonus in effect immediately prior to the date of
termination or (ii) the target bonus in effect immediately prior to the Sale Event, as applicable. 
 This Policy shall be administered by the Company,
and the Company shall have the power and authority to interpret the terms and provisions of this Policy, to make all determinations it deems advisable for the administration of this Policy, to decide all disputes arising in connection with this
Policy and to otherwise supervise administration of this Policy. The Company retains the right to amend, revise, change or end this Policy at any point in the future; provided that this Policy may not be amended or terminated during the period
commencing on the date that it enters into a definitive agreement that if consummated, would result in a Sale Event and ending on the earlier of (i) one (1) year after a Sale Event and (ii) the termination of the definitive agreement
without the consummation of a Sale Event. This Policy does not change the “at-will” employment status of any employee. 

  
 4 

 In the event an employee of the Company is party to an agreement or other arrangement with the Company that
provides greater benefits than set forth in this Policy, such employee shall be entitled to receive the payments or benefits under such other agreement or arrangement and shall not be eligible to receive any payments or benefits under this Policy,
provided that the definition of Cause set forth herein shall continue to apply to the eligibility to receive such other benefits. 
 If due to the
termination of an employee’s relationship with the Company that would trigger any benefits under this Policy, the employee would also qualify for any statutory benefits under applicable employment legislation (including but not limited to,
statutory notice, statutory severance, or similar statutory indemnities related to termination, collectively “Statutory Benefits”) under applicable employment laws, the benefits described under this Policy shall be reduced by such
Statutory Benefits. 
 The payments under this Policy are intended either to be exempt from Section 409A of the Internal Revenue Code of 1986, as
amended (“Section 409A”) under the short-term deferral, separation pay, or other applicable exception, or to otherwise comply with Section 409A. This Policy shall be administered in a manner consistent with such intent. For
purposes of Section 409A, all payments under this Policy shall be considered separate payments. To the extent that any payment or benefit described in this Policy constitutes “non-qualified deferred
compensation” under Section 409A, and to the extent that such payment or benefit is payable upon an employee’s termination of employment, then such payments or benefits shall be payable only upon such employee’s “separation
from service” (determined in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h)). Notwithstanding any provision to the contrary, to the extent an employee is
considered a specified employee under Section 409A and would be entitled during the six-month period beginning on such employee’s separation from service to a payment that is not otherwise excluded
under Section 409A, such payment will not be made until the earlier of (i) the date six months and one day after the employee’s separation from service or (ii) the employee’s death. This Policy may be amended as may be
necessary to fully comply with Section 409A and all related rules and regulations in order to preserve the payments and benefits provided hereunder. The Company makes no representation or warranty and shall have no liability to any employee or
any other person if any provisions of this Policy are determined to constitute deferred compensation subject to Section 409A but do not satisfy an exemption from, or the conditions of, such Section. 

  
 5 

 EXHIBIT A 

PARTICIPATION LETTER 

[DATE] 
 [PARTICIPANT NAME] 

[ADDRESS] 
 Dear [PARTICIPANT]: 

The Board of Directors of Global Blood Therapeutics, Inc. (the “Company”) has designated you as eligible for benefits not in
connection with a Sale Event (the “Non-Sale Benefits”) as set forth in the Company’s Amended and Restated Severance and Change in Control Policy as may be amended from time to time (the
“Policy”). As set forth in the Policy, there are certain eligibility requirements for such Non-Sale Benefits including, but not limited to, your execution of a participation letter as set
forth herein. 
 You agree that to the extent any benefits to which you may be eligible under the Policy are contingent on the termination
of your employment or other service relationship by the Company (or a successor or acquirer) without “cause,” such term shall mean Cause as defined in the Policy. For the avoidance of doubt, the Cause definition in the Policy supersedes
any other definition of such term which may apply to you. 
 This letter and the Policy constitute the entire agreement between you and the
Company with respect to the subject matter hereof and supersede in all respects any and all prior agreements (oral or written) between you and the Company concerning such subject matter. In the event of a conflict between the terms of this letter
and the terms of the Policy, the terms of the Policy shall apply. 
 Congratulations on being selected to be eligible for Non-Sale Benefits under the Policy. 
  

			
	GLOBAL BLOOD THERAPEUTICS, INC.
		
	By:	 	  

		 	Name:
		 	Title:

  

	
	AGREED TO AND ACCEPTED
	
	  

	[Participant Name]

  
 1EX-10.16

 Exhibit 10.16 

GLOBAL BLOOD THERAPEUTICS, INC. 

NON-EMPLOYEE DIRECTOR COMPENSATION POLICY 

The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Global Blood
Therapeutics, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the
Company. In furtherance of this purpose, effective as of January 1, 2021 (the “Effective Date”), all non-employee directors shall be paid compensation for services provided to the Company as set
forth below: 
 Cash Retainers 
 Annual Retainer for
Board Membership: $45,000 for general availability and participation in meetings and conference calls of our Board of Directors (the “Board”). Additional $25,000 for service as lead independent director or non-executive Chairperson of the Board. No additional compensation for attending individual Board meetings. 

Additional Annual Retainers for Committee Membership and Service as Chairperson: 

 

					
	 Audit Committee Chairperson:
	  	$	20,000	 
		
	 Audit Committee member:
	  	$	10,000	 
		
	 Compensation Committee Chairperson:
	  	$	15,000	 
		
	 Compensation Committee member:
	  	$	7,500	 
		
	 Nominating and Corporate Governance Committee Chairperson:
	  	$	10,000	 
		
	 Nominating and Corporate Governance Committee member:
	  	$	5,000	 
		
	 Commercial Committee Chairperson:
	  	$	15,000	 
		
	 Commercial Committee member:
	  	$	7,500	 
		
	 Research and Development Committee Chairperson:
	  	$	15,000	 
		
	 Research and Development Committee member:
	  	$	7,500	 

 No additional compensation for attending individual committee meetings. 

All cash retainers will be paid quarterly, in arrears, or upon the earlier resignation or removal of the non-employee
director. Cash retainers owing to non-employee directors shall be annualized, meaning that with respect to non-employee directors who join the Board during the calendar
year, such amounts shall be pro-rated based on the number of calendar days served by such director.  

 Equity Retainers 

All grants of equity retainer awards to non-employee directors pursuant to this Policy will be automatic and
nondiscretionary and will be made in accordance with the following provisions: 
 (a) Value. For purposes of this Policy,
“Value” means with respect to (i) any award of stock options the grant date fair value of the option (i.e., Black-Scholes Value) determined in accordance with the reasonable assumptions and methodologies employed by the
Company for calculating the fair value of options under ASC 718; and (ii) any award of restricted stock and restricted stock units the product of (A) the average closing market price on The NASDAQ Global Select Market (or such other market on
which the Company’s common stock, par value $0.001 per share (“Common Stock”) is then principally listed) of one share of Common Stock over the trailing 20-trading day period ending on
the trading day immediately preceding the grant date, and (B) the aggregate number of shares pursuant to such award. 
 (b)
Revisions. The Compensation Committee of the Board (the “Compensation Committee”) in its discretion may change and otherwise revise the terms of awards to be granted under this Policy, including, without limitation, the
number of shares subject thereto, for awards of the same or different type granted on or after the date the Compensation Committee determines to make any such change or revision. 

(c) Initial Equity Grants: One-time equity grants to each new
non-employee director upon his/her election to the Board after the Effective Date of (i) an option to purchase shares of Common Stock, with a Value of $415,000, an exercise price per share equal to the
closing price of a share of Common Stock on the date of grant and a term of ten years, provided that the maximum number of shares of Common Stock subject to each such option shall be 11,200 shares and (ii) a grant of restricted stock units with a
Value of $415,000, provided that the maximum number of shares of Common Stock subject to each such grant of restricted stock units shall be 7,200 shares. Such initial option grant shall vest in equal monthly installments during the 36 months
following the date upon which the director is first elected to the Board and such initial restricted stock unit grant shall vest in equal annual installments during the three years following the date upon which the director is first elected to the
Board, in each case subject to the director’s continued service on the Board through each applicable vesting date unless the Board determines that the circumstances warrant continuation of vesting. 

(d) On the date of each Annual Meeting of Stockholders: Annual equity grants to each
non-employee director serving on the Board immediately following the Company’s annual meeting of stockholders consisting of (i) an option to purchase shares of Common Stock, with a Value of $207,500,
an exercise price per share equal to the closing price of a share of Common Stock on the date of grant and a term of ten years, provided that the maximum number of shares of Common Stock subject to each such option shall be 5,600 shares and
(ii) restricted stock units with a Value of $207,500, provided that the maximum number of shares of Common Stock subject to each such grant of restricted stock units shall be 3,600 shares. Such annual option grant shall vest 1/12th on each month following the grant date on the same day of the month as the grant date (and if there is no corresponding day, on the last day of the applicable month) for 11 months and the remaining
1/12th on the earlier of (A) the one-year anniversary of the grant date or (B) the Company’s next annual meeting of stockholders, and
such annual restricted stock unit grant shall 

  
 2 

 
vest on the earlier of (1) the one-year anniversary of the grant date or (2) the Company’s next annual meeting of stockholders, in each case
subject to the director’s continued service on the Board through each applicable vesting date unless the Board determines that the circumstances warrant continuation of vesting. If a new non-employee
director joins our Board on a date other than the date of the Company’s annual meeting of stockholders, then such non-employee director will be granted a pro-rata
portion of the annual equity grants based on the time between such non-employee director’s appointment and the Company’s next annual meeting of stockholders, on the first eligible grant date
following such non-employee director’s appointment to our Board. 
 (e) Additional Equity
Grants: In addition to the foregoing, non-employee directors may also be granted such additional stock options or restricted stock units in such amounts and on such dates as the Board may recommend. 

(f) Sale Event Acceleration. Upon the consummation of a Sale Event (as defined in the Company’s 2015 Stock Option and Incentive
Plan, as may be amended, restated or otherwise modified from time to time), the vesting of all outstanding unvested stock options and restricted stock units granted to each non-employee director under this Policy shall accelerate in full. 

(g) General. The form of option agreement will give directors up to one year following cessation of service as a director to exercise
the options (to the extent vested at the date of such cessation), provided that the director has not been removed for cause. All of the foregoing option grants will have an exercise price equal to the fair market value of a share of Common Stock on
the date of grant. 
 Expenses 
 The Company shall
reimburse all reasonable out-of-pocket expenses incurred by non-employee directors in attending Board and committee meetings.

 Amended and Restated Version Approved by the Board of Directors on September 8, 2016. 

Amended: December 19, 2018. 
 Amended and Restated
Version Approved by the Board of Directors on June 3, 2019. 
 Amended and Restated Version Approved by the Board of Directors on March 24,
2020. 
 Amended and Restated Version Approved by the Board of Directors on December 10, 2020. 

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}]]